Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 367

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain

Open access
Lee, Jeffrey C, Vivanco, Igor, Beroukhim, Rameen, Huang, Julie H. Y, Feng, Whei L, DeBiasi, Ralph M, Yoshimoto, Koji, King, Jennifer C, Nghiemphu, Phioanh, Yuza, Yuki, Xu, Qing, Greulich, Heidi, Thomas, Roman K, Paez, J. Guillermo, Peck, Timothy C, Linhart, David J, Glatt, Karen A, Getz, Gad, Onofrio, Robert, Ziaugra, Liuda, Levine, Ross L, Gabriel, Stacey, Kawaguchi, Tomohiro, O'Neill, Keith, Khan, Haumith, Liau, Linda M, Nelson, Stanley F, Rao, P. Nagesh, Mischel, Paul, Pieper, Russell O, Cloughesy, Tim, Leahy, Daniel J, Sellers, William R, Sawyers, Charles L, Meyerson, Matthew, Mellinghoff, Ingo K · 2006 · PLoS Medicine

Abstract

BACKGROUND: Protein tyrosine kinases are important regulators of cellular homeostasis with tightly controlled catalytic activity. Mutations in kinase-encoding genes can relieve the autoinhibitory constraints on kinase activity, can promote malignant transformation, and appear to be a major determinant of response to kinase inhibitor therapy. Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase inhibitor therapy. METHODS AND FINDINGS: Encouraged by the promising clinical activity of epidermal growth factor receptor (EGFR) kinase inhibitors in treating glioblastoma in humans, we have sequenced the complete EGFR coding sequence in glioma tumor samples and cell lines. We identified novel missense mutations in the extracellular domain of EGFR in 13.6% (18/132) of glioblastomas and 12.5% (1/8) of glioblastoma cell lines. These EGFR mutations were associated with increased EGFR gene dosage and conferred anchorage-independent growth and tumorigenicity to NIH-3T3 cells. Cells transformed by expression of these EGFR mutants were sensitive to small-molecule EGFR kinase inhibitors. CONCLUSIONS: Our results suggest extracellular missense mutations as a novel mechanism for oncogenic EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for treatment of glioblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0030485

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 367

Metadata

Authors
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., Xu, Q., Greulich, H., Thomas, R. K., Paez, J. G., Peck, T. C., Linhart, D. J., Glatt, K. A., Getz, G., Onofrio, R., Ziaugra, L., Levine, R. L., Gabriel, S., Kawaguchi, T., O'Neill, K., Khan, H., Liau, L. M., Nelson, S. F., Rao, P. N., Mischel, P., Pieper, R. O., Cloughesy, T., Leahy, D. J., Sellers, W. R., Sawyers, C. L., Meyerson, M., & Mellinghoff, I. K.
Venue
PLoS Medicine
Published
2006-12-19
Volume
3
Issue
12
Pages
e485
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2117521607
Cited by
367
References
46
FWCI
7.28
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.